Milligan’s Retirement Means New CEO For New Gilead

 
• By Joseph Haas and Mary Jo Laffler

While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.

Businessman covering his face using a white paper with drawn question mark, like a mask, for hiding his identity. Isolated gray wall background.

More from Business

More from Scrip